Raymond James Upgrades CymaBay Therapeutic (CBAY) to Strong Buy as FDA Lifts Clinical Holds on Seladelpar
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse upgraded CymaBay Therapeutic (NASDAQ: CBAY) from Outperform to Strong Buy with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
